Clinical trials: Hyperlipoproteinemia Type II
Coronary Heart Disease, Hyperlipidemia
Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease
Fenofibrate is a drug that acts on the PPAR alpha receptors, increasing HDL-cholesterol and decreasing triglyceride levels. The interaction with these receptors has antiatherogenic actions by regulating the expression con key…
- Trial name
- NCT00552747
- Testing
- fenofibrate
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- National Heart Institute, Mexico
Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients
Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and LDL-C in…
- Trial name
- NCT06712771
- Testing
- VSA003
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Visirna Therapeutics HK Limited
Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
- Trial name
- NCT06112327
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 116 people
- Sponsor
- Verve Therapeutics, Inc.
Familial Hypercholesterolemia, Cholesterol, Elevated
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational…
- Conditions
- Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
- Trial name
- ID-FH (NCT05238519)
- Testing
- Motivational interview (MI)
- Where
- 2 sites in United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Essentia Health
Homozygous Familial Hypercholesterolemia
HoFH, the International Clinical Collaborators Registry
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C)…
- Trial name
- HICC (NCT04815005)
- Testing
- Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Type 2 Diabetes
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00251680
- Testing
- Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy
- Where
- 77 sites in United States, Czechia and 7 more
- Volunteers
- 400 people
- Sponsor
- Takeda
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or…
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- NCT00477594
- Testing
- mipomersen sodium
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kastle Therapeutics, LLC
Hypercholesterolemia
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R…
- Trial name
- NCT04289285
- Testing
- IBI306 450mg SC Q4W, IBI306 600mg SC Q6W
- Where
- China
- Volunteers
- 804 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hyperlipidemia, Diabete Type 2
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers
- Trial name
- NCT07730567
- Testing
- Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B)
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Familial Hypercholesterolemia, Hypercholesterolemia
Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial Hypercholesterolemia
Longitudinal and observational registry-based cohort study of individuals participating in the national digiphysical screening program for Familial Hypercholesterolemia.
- Trial name
- DigiLipids (NCT04929457)
- Where
- Sweden
- Volunteers
- 30,000 people
- Sponsor
- Karolinska Institutet
Familial Hypercholesterolemia, Atherosclerosis
Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia
Familial hypercholesterolaemia (FH) is a genetic disorder characterised by elevated plasma LDLC levels. The causal role of low-density lipoprotein cholesterol (LDLC) in the progression of cardiovascular disease (CVD) is…
- Trial name
- CARDIOMET (NCT05066932)
- Testing
- Additionnal blood samples
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypercholesterolemia
Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH
The purpose is to study Safety and Tolerability.
- Trial name
- NCT01350960
- Testing
- SPC5001, Saline 0.9%
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
Hyperlipidemia, Diabetes Mellitus, Type 2
Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus
The study will investigate the effects of atorvastatin on the concentrations of small, dense LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these effects.
- Conditions
- Hyperlipidemia, Diabetes Mellitus, Type 2, Non-Insulin Dependent Diabetes Mellitus
- Trial name
- ALPIN (NCT00640549)
- Testing
- Atorvastatin
- Where
- 14 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Familial Hypercholesterolemia
Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy
The objectives of this post-surveillance study are to continue to evaluate the safety and effectiveness of the H.E.L.P. System. The safety and effectiveness will be assessed by evaluating the occurrence of death, cardiovascular…
- Trial name
- Secura (NCT00916643)
- Testing
- HELP Secura (apheresis treatment)
- Volunteers
- 113 people
- Sponsor
- B. Braun Medical Inc.
Hypercholesterolemia, Familial, Calcification; Heart
Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
The overarching objective is to evaluate the relationship between diet and coronary artery calcification in patients with heterozygous familial hypercholesterolemia (HeFH). We will recruit adults with HeFH.
- Conditions
- Hypercholesterolemia, Familial, Calcification; Heart, Diet Habit
- Trial name
- FH-CAC (NCT04837638)
- Testing
- Diet
- Where
- Canada
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Laval University
Hypercholesterolemia, Familial, Hyperlipidemia
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial…
- Trial name
- NCT00134485
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Hypertension, Angina Pectoris
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined.
- Conditions
- Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- NCT01107743
- Testing
- Amlodipine/Atorvastatin
- Volunteers
- 1,291 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes Mellitus, Type 2, Hypercholesterolemia
The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients
The purpose of this study is to verify the possible effects of OMACOR(omega-3 fatty acid) on the percentage change of small dense LDL fraction in type 2 diabetic patients with combined hyperlipidemia, we perform open-label…
- Conditions
- Diabetes Mellitus, Type 2, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT00758927
- Testing
- Omega-3 acid 4 grams per day
- Where
- 3 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Inje University
Hypercholesterolemia
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
The primary objective of the study is to assess the pharmacodynamic (PD) effect of alirocumab on serum low density lipoprotein cholesterol (LDL-C) during 14 weeks of subcutaneous (SC) administered alirocumab in patients with…
- Trial name
- NCT01604824
- Testing
- Alirocumab
- Where
- 4 sites in United States, France
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).
- Trial name
- REALIZE (NCT01524289)
- Testing
- Anacetrapib
- Volunteers
- 306 people
- Sponsor
- Merck Sharp & Dohme LLC